Antibody Drug Conjugate Development and Manufacture
Piramal
PRA Prepares to Go Public with Confidential SEC Filing
 |
US CRO PRA is proposing to go public again, more than six years since it was taken private, according to a confidential draft registration statement submitted to the US SEC. Related news |
News in brief
Although preclinical work for CROs has fallen flat in recent quarters, Covance is looking to take advantage of the industry’s shift to early biologic developments and lead optimization.
Cobra Biologics is confident it can win the commercial contract for Vaccibody AS’ candidate DNA vaccine, citing its production platform and recent capacity expansion as key.
Just days after raising more than $1B in its IPO, Quintiles announced Wednesday it signed a five-year clinical development agreement with Merck Serono.
Proposed UK “animal research” labelling laws may backfire if improvements in culture-based toxicology testing continue, according to in vitro CRO Cyprotex.
Global Industry News
Janssen's Manufacturing Problems May Lead to Criminal Charges in Korea from in-PharmaTechnologist.com
Though Janssen Korea says it is confident it will resolve its manufacturing issues, product recall and suspensions could be followed by lawsuits and imprisonment.
Russia Working to Align Biologics Regs with International Standards from in-PharmaTechnologist.com
Regulators and the drug industry met in Moscow last week to develop a framework for firms developing biologics and biosimilars in the Russian Federation.
Dispatches from Interphex
EMD Millipore Talks New Single-Use Chromatography Tech from in-PharmaTechnologist.com
EMD Millipore says its new chromatography tech can help manufacturers avoid compromising their processes when switching from multi-use to single use
People on the Move: Pharma Jobs from in-PharmaTechnologist.com
In-Pharmatechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals, including news from Bayer, Valeant and Eisai.
Pfizer Puts Lipitor Site Up For Sale as Patent Expiration Causes Over-Capacity from in-PharmaTechnologist.com
Lower sales of off-patent former blockbuster Lipitor have prompted Pfizer to try and sell off its third Irish API plant in as many years.
Hot topics
Spotlight
  Executives Raise Questions on Clinical Trial Sponsors’ Oversight of CROsTension between clinical trial sponsors and CROs in terms of CRO oversight may not be relieved any... |